CytomX publishes corporate presentation on PROBODY platform oncology pipeline advances

CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc.

CTMX

0.00
  • CytomX highlighted lead clinical program varsetatug masetecan (Varseta-M), an EpCAM-targeted Topo-1 PROBODY ADC being developed for metastatic colorectal cancer, with Phase 1 dose optimization data expected in 2H 2026.
  • Late-line mCRC interim Phase 1 dose expansion data showed confirmed ORR of 20% at 8.6 mg/kg (4/20) and 32% at 10 mg/kg (6/19), with median PFS of 6.8 months at 8.6 mg/kg and 7.1 months at 10 mg/kg.
  • Combination development advanced with Varseta-M with bevacizumab initiated in Q1 2026 for 2L/3L mCRC, with a Phase 1/2 triplet with bevacizumab and chemotherapy slated to start in 2H 2026.
  • Second clinical program CX-801, a PROBODY interferon alpha-2b, targets advanced melanoma, with Phase 1 data for CX-801 with KEYTRUDA due by 2026 year-end.
  • Cash position stood at $347 million as of Q1 2026, with runway projected into 2H 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.